South Korean biopharma sees way forward after PhIII eye disease trial failure
HanAll BioPharma’s dry eye drug failed to meet either of the primary endpoints in a Phase III clinical trial, but the company said it still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
